Reminder: Rosa Impact webinar series on September 19 by Professor Rowland

Addressing drug development questions with physiologically based pharmacokinetics By: Malcolm Rowland, PhD, Professor Emeritus, University of Manchester September 19, 2012 12:00 – 1:00 pm EDT Historically, pharmacokinetics has been descriptive and limited in its informativeness. Physiologically based pharmacokinetics, and associated models, offer a mechanistic, highly informative approach to the subject. The principles behind PBPK will be described and its application will be illustrated within the context of drug development, both preclinical prediction of human PK and clinical development, and in addressing regulatory questions. The purpose of the “Impact” series is to foster the use of M&S activities in all phases of drug development by illustrating the advantages and enhancing the applicability of M&S in product discovery, development, and marketing programs. The series is intended for drug development project team members from discovery to phase 4 clinical trials. This includes pharmacologists, ADME scientists, PK/PD modelers, clinical pharmacologists, clinical development team members, regulatory affairs specialists, and other interested professionals. Register for this free webinar at www.rosaandco.com/webinar. After registering you will receive a confirmation email containing information about joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at www.rosaandco.com/webinar. Please allow 5-10 minutes for a Java applet to be installed on your computer prior to joining our webinar series for the first time. Toufigh Gordi, PhD President PK/PD and Clinical Pharmacology Services Rosa & Co. LLC 751 Laurel St., Ste. 127, San Carlos, CA 94070 408-480-7314 <mailto:[email protected]> [email protected] http://www.rosaandco.com/ www.rosaandco.com The information contained in this e-mail message, e-mail message sequence, and/or any enclosures is confidential, and it may be privileged and protected from unauthorized use and/or disclosure. If you are not the intended recipient, any use, dissemination, distribution, or copying is strictly prohibited. If you received this e-mail in error, PLEASE NOTIFY THE SENDER immediately and destroy this message, any enclosures, and any copies of the message and/or the enclosures. Thank you.